C4 Therapeutics Stock Current Valuation
| CCCC Stock | USD 2.65 0.14 5.02% |
Valuation analysis of C4 Therapeutics helps investors to measure C4 Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of February 27, 2025, Enterprise Value Over EBITDA is expected to decline to -1.74. In addition to that, Enterprise Value Multiple is expected to decline to -1.74. Fundamental drivers impacting C4 Therapeutics' valuation include:
Overvalued
Today
Please note that C4 Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of C4 Therapeutics is based on 3 months time horizon. Increasing C4 Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since C4 Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CCCC Stock. However, C4 Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.65 | Real 2.41 | Target 16.38 | Hype 2.65 | Naive 2.66 |
The real value of CCCC Stock, also known as its intrinsic value, is the underlying worth of C4 Therapeutics Company, which is reflected in its stock price. It is based on C4 Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of C4 Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of C4 Therapeutics helps investors to forecast how CCCC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of C4 Therapeutics more accurately as focusing exclusively on C4 Therapeutics' fundamentals will not take into account other important factors: C4 Therapeutics Company Current Valuation Analysis
C4 Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current C4 Therapeutics Current Valuation | 7.69 M |
Most of C4 Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, C4 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CCCC Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for C4 Therapeutics is extremely important. It helps to project a fair market value of CCCC Stock properly, considering its historical fundamentals such as Current Valuation. Since C4 Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of C4 Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of C4 Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
CCCC Current Valuation Historical Pattern
Today, most investors in C4 Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various C4 Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of C4 Therapeutics current valuation as a starting point in their analysis.
C4 Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, C4 Therapeutics has a Current Valuation of 7.69 M. This is 99.95% lower than that of the Biotechnology sector and 99.83% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.95% higher than that of the company.
CCCC Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses C4 Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics of similar companies.C4 Therapeutics is currently under evaluation in current valuation category among its peers.
C4 Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of C4 Therapeutics from analyzing C4 Therapeutics' financial statements. These drivers represent accounts that assess C4 Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of C4 Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 1.5B | 288.3M | 280.5M | 322.5M | 306.4M | |
| Enterprise Value | 1.3B | 1.4B | 345.7M | 224.9M | 258.6M | 245.7M |
C4 Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, C4 Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to C4 Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
CCCC Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (1.84) % | ||||
| Current Valuation | 7.69 M | ||||
| Shares Outstanding | 70.59 M | ||||
| Shares Owned By Insiders | 11.57 % | ||||
| Shares Owned By Institutions | 92.00 % | ||||
| Number Of Shares Shorted | 7.4 M | ||||
| Price To Book | 0.81 X | ||||
| Price To Sales | 5.56 X | ||||
| Revenue | 20.76 M | ||||
| Gross Profit | (74.85 M) | ||||
| EBITDA | (122.1 M) | ||||
| Net Income | (132.49 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 70.98 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 3.44 X | ||||
| Cash Flow From Operations | (106.84 M) | ||||
| Short Ratio | 3.78 X | ||||
| Earnings Per Share | (1.71) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 15.0 | ||||
| Number Of Employees | 145 | ||||
| Beta | 2.96 | ||||
| Market Capitalization | 187.06 M | ||||
| Total Asset | 376.45 M | ||||
| Retained Earnings | (528.38 M) | ||||
| Working Capital | 228.42 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
| Net Asset | 376.45 M |
About C4 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze C4 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out C4 Therapeutics Piotroski F Score and C4 Therapeutics Altman Z Score analysis. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth 0.387 | Return On Assets | Return On Equity |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.